Clinical value of liver cancer staging in predicting the survival time in Chinese patients after receiving TACE: comparison of Hong Kong liver cancer staging system with Barcelona clinic liver cancer staging system
10.3969/j.issn.1008-794X.2017.12.006
- VernacularTitle:比较香港肝癌分期和巴塞罗那肝癌分期对TACE后生存的预测作用
- Author:
Li CHEN
1
;
Jinhe GUO
;
Guangyu ZHU
;
Binyan ZHONG
;
Sheng XU
;
Gaojun TENG
Author Information
1. 210009,南京 东南大学附属中大医院介入与血管外科
- Keywords:
primary hepatocellular carcinoma;
transarterial chemoembolization;
Barcelona Clinic Liver Cancer Staging;
Hong Kong Liver Cancer Staging
- From:
Journal of Interventional Radiology
2017;26(12):1088-1092
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the prognostic ability of Hong Kong Liver Cancer (HKLC) staging system with that of Barcelona Clinic Liver Cancer (BCLC) staging system for Chinese patients with hepatocellular carcinoma (HCC) after receiving transarterial chemoembolization (TACE).Methods The clinical data of 180 Chinese patients with primary HCC,who were treated with TACE during the period from August 2008 to December 2015,were retrospectively analyzed.HCC staging of each patient was scored by two staging methods separately.Kaplan-Meier analysis was adopted to separately calculate the median survival time of each stage that was judged by the two staging methods.The likelihood ratio (LR) x2 values,the Akaike information criterion (AIC) value and Harrell's C value of the two staging methods were calculated.Results Statistically significant differences in the survival time of each period existed between the two staging systems.AIC value,LRx2 value and Harrell's C value of HKLC staging system were 1360,66.6,and 0.813 respectively,while those of BCLC staging system were 1365,61.8,and 0.772 respectively.Conclusion Compared with BCLC staging,HKLC staging is more suitable for predicting the survival time of Chinese patients with primary liver cancer treated with TACE.
